Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 in HER2-negative, EGFR-positive recurrent or metastatic breast cancer
NCT07406542Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 3, randomised, open-label trial of CPO301 in breast cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoint: Progression-Free Survival at 36 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07406542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406542.